22nd Century Group Approved to List Common Stock on NYSE MKT
March 06 2014 - 5:30PM
Business Wire
22nd Century Group, Inc. (OTCQB:XXII) today announced that the
Company received approval to list its common stock on the NYSE MKT.
Trading on the NYSE MKT is expected to commence on Tuesday, March
11, 2014 under the Company's current symbol, XXII. In connection
with this NYSE MKT listing, 22nd Century Group will cease trading
on the OTCBB and OTCQB.
“The listing of our common stock on NYSE MKT is an important
milestone for the Company since many institutional investors and
retail brokers looking to build a position in 22nd Century Group
stock are not allowed to purchase OTC Bulletin Board stocks,”
stated Joseph Pandolfino, 22nd Century’s Founder and CEO. “22nd
Century Group in recent months has implemented important components
of its business plan and has delivered strong financial growth, and
we anticipate our transition to the NYSE MKT will greatly
facilitate continued growth in shareholder value as we meet
additional upcoming milestones.”
“We welcome 22nd Century Group, Inc. to the NYSE MKT’s listed
company community,” said Scott Cutler, Executive Vice President
& Head of Global Listings, NYSE Euronext. “We congratulate 22nd
Century Group on its first day of trading on the NYSE MKT and look
forward to a long-standing partnership with the company and its
shareholders.”
22nd Century Group selected Virtu Financial as its Designated
Market Maker on the NYSE MKT.
22nd Century Group is currently scheduled to ring the opening
bell at the New York Stock Exchange on Tuesday June 17, 2014.
For additional information, please visit:
www.xxiicentury.com.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company whose proprietary
technology allows for the levels of nicotine and other nicotinic
alkaloids (e.g., nornicotine, anatabine and anabasine) in the
tobacco plant to be decreased or increased through genetic
engineering and plant breeding. 22nd Century owns or is the
exclusive licensee of 114 issued patents in 78 countries plus an
additional 38 pending patent applications. Goodrich Tobacco
Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned
subsidiaries of 22nd Century. Goodrich Tobacco is focused on
premium commercial tobacco products and potentially less harmful
cigarettes. Hercules Pharmaceuticals is focused on X-22, a
prescription smoking cessation aid in development.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2013, filed on January 30, 2014,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
Redington, Inc.Tom Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From May 2023 to May 2024